Skip to main content

Table 3 Efficacy of different classes of anti-HCV agents with respect to resistance profile, genotype coverage and antiviral activity

From: New hepatitis C therapies in clinical development

  NS3 Protease Inhibitors NS5A Inhibitors NS5B Nuc. Inhibitors NS5B Non-Nuc. Inhibitors Cyclophilin Inhibitors PEG-Interferon alfa
Barrier to resistance low low high low high very high
Genotype coverage + ++ +++ - ++ +++
antiviral activity +++ +++ ++ ++ +/++ +